Jenny J. Ko

880 total citations
32 papers, 633 citations indexed

About

Jenny J. Ko is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jenny J. Ko has authored 32 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 11 papers in Surgery. Recurrent topics in Jenny J. Ko's work include Cancer Genomics and Diagnostics (5 papers), Renal cell carcinoma treatment (4 papers) and Testicular diseases and treatments (4 papers). Jenny J. Ko is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Renal cell carcinoma treatment (4 papers) and Testicular diseases and treatments (4 papers). Jenny J. Ko collaborates with scholars based in Canada, United States and Japan. Jenny J. Ko's co-authors include Georg A. Bjarnason, Frede Donskov, Takeshi Yuasa, Sun Young Rha, Brian I. Rini, Ulka N. Vaishampayan, Jennifer J. Knox, Sumanta K. Pal, Lori Wood and Nils Kroeger and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Jenny J. Ko

29 papers receiving 623 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jenny J. Ko Canada 10 398 273 238 158 148 32 633
Michael W. Drazer United States 15 278 0.7× 192 0.7× 121 0.5× 94 0.6× 181 1.2× 38 769
Guillaume Mouillet France 11 319 0.8× 212 0.8× 146 0.6× 105 0.7× 77 0.5× 33 465
Carmine D’Aniello Italy 17 350 0.9× 147 0.5× 242 1.0× 167 1.1× 239 1.6× 33 720
Hidekazu Tachibana Japan 14 487 1.2× 364 1.3× 160 0.7× 73 0.5× 194 1.3× 63 643
Q.D. Trinh United States 11 535 1.3× 314 1.2× 199 0.8× 120 0.8× 212 1.4× 24 743
Antonio Santo Italy 16 402 1.0× 357 1.3× 121 0.5× 110 0.7× 83 0.6× 55 786
Fabio A. Schutz United States 11 381 1.0× 299 1.1× 263 1.1× 136 0.9× 177 1.2× 30 685
Tania Mariani United States 7 580 1.5× 203 0.7× 486 2.0× 258 1.6× 443 3.0× 8 999
Jitka Abrahámová Czechia 10 182 0.5× 147 0.5× 168 0.7× 91 0.6× 95 0.6× 44 406
Ilya Tsimafeyeu Russia 15 360 0.9× 216 0.8× 325 1.4× 143 0.9× 85 0.6× 111 628

Countries citing papers authored by Jenny J. Ko

Since Specialization
Citations

This map shows the geographic impact of Jenny J. Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenny J. Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenny J. Ko more than expected).

Fields of papers citing papers by Jenny J. Ko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenny J. Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenny J. Ko. The network helps show where Jenny J. Ko may publish in the future.

Co-authorship network of co-authors of Jenny J. Ko

This figure shows the co-authorship network connecting the top 25 collaborators of Jenny J. Ko. A scholar is included among the top collaborators of Jenny J. Ko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jenny J. Ko. Jenny J. Ko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ko, Jenny J., Lawrence Mbuagbaw, Scott Tyldesley, et al.. (2024). Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE). Canadian Urological Association Journal. 18(7). 1 indexed citations
2.
Schönlau, Elena, David C. Müller, Gillian Vandekerkhove, et al.. (2023). Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.. Journal of Clinical Oncology. 41(16_suppl). 4577–4577.
3.
Wang, Christine, et al.. (2023). Patient, disease, and survival outcomes for stage IB to stage IV cervical cancer—A population study. Women s Health. 19. 902575239–902575239. 3 indexed citations
4.
Ko, Jenny J., Julia Adams, Katherine Sunderland, et al.. (2022). Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate. Canadian Urological Association Journal. 16(11). E528–E532. 2 indexed citations
5.
Le, Nhu D., et al.. (2022). Adjuvant chemotherapy and radiation for patients with high-risk stage I endometrial cancer treated with curative intent surgery: impact on recurrence and survival. International Journal of Gynecological Cancer. 32(4). 508–516. 3 indexed citations
6.
Lavallée, Luke T., Christopher Morash, Fred Saad, et al.. (2022). Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study.. Journal of Clinical Oncology. 40(6_suppl). 252–252. 1 indexed citations
7.
Ko, Jenny J., et al.. (2021). Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer. Current Oncology. 28(5). 3812–3824. 11 indexed citations
8.
Ko, Jenny J., Tamara Shenkier, Jessica Simon, et al.. (2020). Serious Illness Conversation–Evaluation Exercise: A Novel Assessment Tool for Residents Leading Serious Illness Conversations. SHILAP Revista de lepidopterología. 1(1). 280–290. 3 indexed citations
9.
Khan, Omar, Ellen Cusano, Soundouss Raissouni, et al.. (2019). Immediate-term cognitive impairment following intravenous (IV) chemotherapy: a prospective pre-post design study. BMC Cancer. 19(1). 150–150. 15 indexed citations
10.
Roy, Soumyajit, et al.. (2019). Small cell carcinoma of cervix: A population-based study evaluating standardized provincial treatment protocols. Gynecologic Oncology Reports. 27. 54–59. 7 indexed citations
11.
Cheung, Winson Y., et al.. (2018). Causes of mortality in older patients with stage 3 colon cancer. Journal of Geriatric Oncology. 10(1). 138–142. 8 indexed citations
12.
13.
Ko, Jenny J., Jodi Siever, Desirée Hao, Richard J. Simpson, & Harold Lau. (2016). Adenoid Cystic Carcinoma of Head and Neck: Clinical Predictors of Outcome from a Canadian Centre. Current Oncology. 23(1). 26–33. 49 indexed citations
14.
Ko, Jenny J., Brandon Bernard, Ben Tran, et al.. (2016). Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy. Journal of Clinical Oncology. 34(7). 714–720. 29 indexed citations
15.
Ko, Jenny J., Hagen F. Kennecke, Howard J. Lim, et al.. (2015). Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. Clinical Colorectal Cancer. 15(2). 179–185. 42 indexed citations
16.
Lupichuk, Sasha, Lihong Zhong, Jenny J. Ko, et al.. (2015). Discharge to Primary Care for Survivorship Follow-Up: How Are Patients With Early-Stage Breast Cancer Faring?. Journal of the National Comprehensive Cancer Network. 13(6). 762–771. 9 indexed citations
17.
18.
Ko, Jenny J., Alexander C. Klimowicz, Amanda Jagdis, et al.. (2015). ATM, THMS, and RRM1 protein expression in nasopharyngeal carcinomas treated with curative intent. Head & Neck. 38(S1). 8 indexed citations
19.
Ko, Jenny J., Toni K. Choueiri, Brian I. Rini, et al.. (2014). First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. British Journal of Cancer. 110(8). 1917–1922. 58 indexed citations
20.
Ko, Jenny J., et al.. (2012). Vitamin A, folate, and choline as a possible preventive intervention to fetal alcohol syndrome. Medical Hypotheses. 78(4). 489–493. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael W. Drazer Breakdown of academic impact, for papers by Guillaume Mouillet Breakdown of academic impact, for papers by Carmine D’Aniello Breakdown of academic impact, for papers by Hidekazu Tachibana Breakdown of academic impact, for papers by Q.D. Trinh Breakdown of academic impact, for papers by Antonio Santo Breakdown of academic impact, for papers by Fabio A. Schutz Breakdown of academic impact, for papers by Tania Mariani Breakdown of academic impact, for papers by Jitka Abrahámová Breakdown of academic impact, for papers by Ilya Tsimafeyeu
Rankless by CCL
2026